Progyny

Progyny FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Progyny (PGNY) as of Nov 12, 2026 is 327.72 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 319.68 % — a change of 2.52% (higher).

FCF Conversion

327.72 %

YoY

2.52%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Progyny is 2025 327.72 % . FCF Conversion Rate (FCF/EBITDA) of Progyny was 2024 319.68 % . It decreases by 2.52% higher compared to the previous year.

The Progyny FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
256.13 USD
Jan 1, 2019
52.40 USD
Jan 1, 2020
75.69 USD
Jan 1, 2021
36.35 USD
Jan 1, 2022
254.15 USD
Jan 1, 2023
298.48 USD
Jan 1, 2024
319.68 USD
Jan 1, 2025
327.72 USD
The Progyny FCF Conversion history
YEARFCF ConversionYoY
327.72 %+2.52%
319.68 %+7.10%
298.48 %+17.45%
254.15 %+599.14%
36.35 %-51.97%
75.69 %+44.46%
52.40 %-79.54%
256.13 %+216.21%
81.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Progyny Stock analysis

What does Progyny do? Progyny Inc. is a company specializing in reproductive medicine and fertility treatments. It was founded in New York City in 2008 and has been listed on the NASDAQ stock exchange since 2019. The idea for Progyny arose when founder Gina Bartasi herself had difficulty getting pregnant and was searching for support and transparent information. She recognized the need to offer a better and more accessible service for people with fertility problems, thus founding Progyny. Progyny's business model is to offer employers a fertility benefit to help their employees, especially women, with family planning. It provides customized fertility treatments and financial assistance through its innovative programs. This allows employers to position themselves as progressive and inclusive while also increasing the bond and well-being of their employees. The different divisions of Progyny include fertility management, fertility measurement and monitoring, and fertility benefits. The fertility management solutions provide companies with comprehensive care for their employees, including counseling and support on fertility and family planning. They also provide access to an exclusive network practice specializing in reproductive medicine, including in vitro fertilization (IVF) and egg donation. The fertility measurement and monitoring program offers a personalized fertility profile that allows employees to track their fertility status to maximize their chances of a successful pregnancy. Progyny utilizes advanced methods of artificial intelligence and machine learning for this purpose. Progyny's fertility benefits include financial support for fertility treatments and medications that are not normally covered by health insurance. Additionally, the company offers a unique membership option that provides unlimited access to master fertility practices for one year. Progyny also offers a comprehensive patient experience through world-leading doctors and a patented technology platform. The platform provides support in navigating the fertility process and ensures that patients receive the best possible medical and financial care. Overall, Progyny has a significant impact on the field of reproductive medicine. With an innovative solution tailored to the needs of employers and strong support for aspiring parents, the company achieves a higher success rate in pregnancy compared to traditional fertility treatments. Progyny's technology platform improves workflow efficiency and communication in the practice, leading to a better patient experience and greater engagement. Overall, Progyny offers a holistic solution for employers and employees tailored to the unique challenges of family planning and fertility. With innovative approaches and a focus on the well-being of female employees, the company has taken a unique position in the market and is expected to continue to play a strong role in the industry. Progyny is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Progyny stock

FCF Conversion Rate (FCF/EBITDA) of Progyny is 327.72 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Progyny changed from 319.68 % to 327.72 %, representing a 2.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Progyny since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Progyny with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Progyny

All Key Metrics — Progyny